The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates
Epigallocatechin gallate (EGCG) is the predominant bioactive catechin in green tea, and it has been ascribed a range of beneficial health effects. Current increases in obesity and non-alcoholic fatty liver disease (NAFLD) rates represent a persistent and burdensome threat to global public health. Wh...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/13/1/206 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832588993877770240 |
|---|---|
| author | Ruike Yan Yanli Cao |
| author_facet | Ruike Yan Yanli Cao |
| author_sort | Ruike Yan |
| collection | DOAJ |
| description | Epigallocatechin gallate (EGCG) is the predominant bioactive catechin in green tea, and it has been ascribed a range of beneficial health effects. Current increases in obesity and non-alcoholic fatty liver disease (NAFLD) rates represent a persistent and burdensome threat to global public health. While many clinical studies have demonstrated that EGCG is associated with positive effects on various health parameters, including metabolic biomarkers, waist circumference, and body weight when consumed by individuals affected by obesity and NAFLD, there are also some reports suggesting that it may entail some degree of hepatotoxicity. The present review provides a comprehensive summary of the extant clinical findings pertaining to the safety and effectiveness of EGCG in managing obesity and NAFLD, with a particular focus on how treatment duration and dose level affect the bioactivity of this compound. |
| format | Article |
| id | doaj-art-95c16b7125c94705b9e183fd737bc913 |
| institution | Kabale University |
| issn | 2227-9059 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj-art-95c16b7125c94705b9e183fd737bc9132025-01-24T13:24:23ZengMDPI AGBiomedicines2227-90592025-01-0113120610.3390/biomedicines13010206The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent UpdatesRuike Yan0Yanli Cao1Department of Endocrinology and Metabolism, Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, ChinaDepartment of Endocrinology and Metabolism, Institute of Endocrinology, NHC Key Laboratory of Diagnosis and Treatment of Thyroid Diseases, The First Affiliated Hospital of China Medical University, Shenyang 110001, ChinaEpigallocatechin gallate (EGCG) is the predominant bioactive catechin in green tea, and it has been ascribed a range of beneficial health effects. Current increases in obesity and non-alcoholic fatty liver disease (NAFLD) rates represent a persistent and burdensome threat to global public health. While many clinical studies have demonstrated that EGCG is associated with positive effects on various health parameters, including metabolic biomarkers, waist circumference, and body weight when consumed by individuals affected by obesity and NAFLD, there are also some reports suggesting that it may entail some degree of hepatotoxicity. The present review provides a comprehensive summary of the extant clinical findings pertaining to the safety and effectiveness of EGCG in managing obesity and NAFLD, with a particular focus on how treatment duration and dose level affect the bioactivity of this compound.https://www.mdpi.com/2227-9059/13/1/206epigallocatechin gallateobesitynon-alcoholic fatty liver diseasemetabolic disease |
| spellingShingle | Ruike Yan Yanli Cao The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates Biomedicines epigallocatechin gallate obesity non-alcoholic fatty liver disease metabolic disease |
| title | The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates |
| title_full | The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates |
| title_fullStr | The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates |
| title_full_unstemmed | The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates |
| title_short | The Safety and Efficacy of Dietary Epigallocatechin Gallate Supplementation for the Management of Obesity and Non-Alcoholic Fatty Liver Disease: Recent Updates |
| title_sort | safety and efficacy of dietary epigallocatechin gallate supplementation for the management of obesity and non alcoholic fatty liver disease recent updates |
| topic | epigallocatechin gallate obesity non-alcoholic fatty liver disease metabolic disease |
| url | https://www.mdpi.com/2227-9059/13/1/206 |
| work_keys_str_mv | AT ruikeyan thesafetyandefficacyofdietaryepigallocatechingallatesupplementationforthemanagementofobesityandnonalcoholicfattyliverdiseaserecentupdates AT yanlicao thesafetyandefficacyofdietaryepigallocatechingallatesupplementationforthemanagementofobesityandnonalcoholicfattyliverdiseaserecentupdates AT ruikeyan safetyandefficacyofdietaryepigallocatechingallatesupplementationforthemanagementofobesityandnonalcoholicfattyliverdiseaserecentupdates AT yanlicao safetyandefficacyofdietaryepigallocatechingallatesupplementationforthemanagementofobesityandnonalcoholicfattyliverdiseaserecentupdates |